Metastatic

Type: Keyphrase
Name: Metastatic
First reported 9 hours ago - Updated 18 mins ago - 2 reports

Protein therapy to stop cancer from spreading

By | IANS India Private Limited/Yahoo India News  –New York, Sep 22 (IANS) A protein therapy may soon offer a safe and effective alternative to chemotherapy that doctors today apply to try to slow or stop cancer from spreading.The experimental therapy ... [Published Yahoo! Malaysia - 18 mins ago]
First reported 2 hours ago - Updated 2 hours ago - 1 reports

Prolonged complete response after treatment withdrawal in HER2-overexpressed, hormone ...

Metastatic breast cancer has consistently been viewed as a non-curable disease. Specific palliative treatments such as chemotherapy and hormone therapy have resulted in a mean overall survival of approximately 30 months.While cases of prolonged complete ... [Published 7thSpace - 2 hours ago]
First reported 7 hours ago - Updated 7 hours ago - 1 reports

Immature blood vessels linked to poor sunitinib response

medwireNews: Patients with clear-cell renal cell carcinoma (RCC) with relatively mature blood vessels respond better to sunitinib and have fewer metastatic sites than those with immature vessels, a study has found.Not all patients with metastatic (m)RCC ... [Published MedWire News - 7 hours ago]
First reported 16 hours ago - Updated 16 hours ago - 1 reports

Be a Good One

By Natalie PalmerMy story begins with a quote by Abraham Lincoln, with whom I share a birthday: “Whatever you are, be a good one.” Many years ago this became the mission statement of my life and remains so to this day.I am a person with metastatic breast ... [Published Breast Cancer Wellness - 16 hours ago]
First reported 22 hours ago - Updated 21 hours ago - 2 reports

Forum Post: RE: Diffuse multiple focus metastatic bony lesions and collapse of T8

Morning Patsy,  T8 is in the thoracic part of the spine (thoracic is chest) I'll put a spine image in so you can see where T8 is.Roughly translated it means they have found bone mets 'cluster of cells' in multiple areas of her spine and the cancer has ... [Published Macmillan Cancer Support - 21 hours ago]
First reported Sep 20 2014 - Updated Sep 20 2014 - 1 reports

LPATH TO SELL STOCK IN $12.5M OFFERING

Drug developer Lpath said Friday that it has agreed to sell $12.5 million of stock in a direct offering to investors.The San Diego biotech company recently announced what it described as encouraging interim results in a Phase 2a clinical trial of Asonep, ... [Published U-T San Diego - Sep 20 2014]
First reported Sep 20 2014 - Updated Sep 20 2014 - 1 reports

Tumor subtype provided prognostic factor for survival after WBRT for metastatic breast cancer

SAN FRANCISCO — Vipin Das Villgran, MD , medical resident at University of Pittsburgh Medical Center, discusses study results which found that tumor subtype predicted survival among patients with breast cancer who underwent whole-brain radiation therapy ... [Published Orthopedics Today - Sep 20 2014]
First reported Sep 20 2014 - Updated Sep 20 2014 - 1 reports

Comment Realworld experience with abiraterone

In The Lancet Oncology, Cora Sternberg and colleagues present results of an early-access protocol trial of abiraterone acetate for treatment of patients with metastatic castration-resistant prostate cancer who had progressed after taxane chemotherapy ... [Published BioPortfolio - Sep 20 2014]
First reported Sep 18 2014 - Updated Sep 19 2014 - 2 reports

Hope for metastatic prostate cancer

MILWAUKEE, Wis. (Ivanhoe Newswire) -- After skin cancer, prostate cancer is the most common cancer in men. When caught early, it can often be cured. But when it spreads, most patients will die within five years. Now a new treatment approach could lengthen ... [Published My Sun Coast - Sep 18 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 2 reports

GSK's Melanoma Pill Gets NICE Nod

With GlaxoSmithKline agreeing to provide its melanoma pill Tafinlar at an undisclosed discount price, the National Institute for Health and Care Excellence (NICE) in UK has recommended the drug for treating unresectable or metastatic BRAF V600 mutation-positive ... [Published MedIndia - Sep 19 2014]
First reported Sep 17 2014 - Updated Sep 18 2014 - 3 reports

New non-invasive technique could revolutionize the imaging of metastatic cancer

Bioluminescence, nanoparticles, gene manipulation – these sound like the ideas of a science fiction writer, but, in fact, they are components of an exciting new approach to imaging local and metastatic tumors. In preclinical animal models of metastatic ... [Published US Society of Nuclear Medicine - Sep 18 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 2 reports

Enzalutamide may offer chemotherapy alternative in metastatic castrationresistant prostate cancer

The United States Food and Drug Association has approved the use of enzalutamide for patients with metastatic castration-resistant prostate cancer (CRPC).Enzalutamide is an androgen receptor inhibitor that is taken orally once a day.It was...Related Biotechnology, ... [Published BioPortfolio - Sep 18 2014]

Quotes

"It could open up a new approach to cancer treatment" Giaccia added
"The majority of patients who succumb to cancer fall prey to metastatic forms of the disease" said Jennifer Cochran, an associate professorprofessor of bioengineering who describes a new therapeutic approach in Nature Chemical Biology
"So one therapeutic decoy might potentially affect all three related proteins that are critical in cancer development and progression" Dranoff said
"Whenever Pfizer doses the first Phase 3 patient, there's another big chunk of money at that point in time as well," he said. "This might very well be all the money we need -- forever."

More Content

All (2035) | News (1584) | Reports (0) | Blogs (407) | Audio/Video (1) | Fact Sheets (2) | Press Releases (25)
sort by: Date | Relevance
Protein therapy to stop cancer from spreading [Published Yahoo! Malaysia - 19 mins ago]
Blood Test for Receptor Predicts Prostate Cance... [Published Lab Medica - 1 hour ago]
Prolonged complete response after treatment wit... [Published 7thSpace - 2 hours ago]
Immature blood vessels linked to poor sunitinib... [Published MedWire News - 7 hours ago]
Stanford researchers create 'evolved' protein t... [Published Bio-Medicine - 9 hours ago]
Ethernet I/O modules run cyclotron control syst... [Published Pro Health Service Zone - 12 hours ago]
Scientists create 'evolved' protein that may st... [Published PhysOrg.com - 13 hours ago]
Be a Good One [Published Breast Cancer Wellness - 16 hours ago]
Forum Post: RE: Diffuse multiple focus metastat... [Published Macmillan Cancer Support - 21 hours ago]
Forum Post: Diffuse multiple focus metastatic b... [Published Macmillan Cancer Support - 22 hours ago]
PREVAIL Trial Investigator Discusses Pre-Chemo ... [Published OncLive - Sep 20 2014]
LPATH TO SELL STOCK IN $12.5M OFFERING [Published U-T San Diego - Sep 20 2014]
New drug hope for West skin cancer victims [Published Western Morning News - Sep 20 2014]
William Fogwell [Published Cedar Rapids Gazette - Sep 20 2014]
PD-L1 Positivity Confers Worse Outcomes in Non–... [Published Cancernetwork.com - Sep 20 2014]
Tumor subtype provided prognostic factor for su... [Published Orthopedics Today - Sep 20 2014]
Comment Realworld experience with abiraterone [Published BioPortfolio - Sep 20 2014]
Pain Therapeutics (PTIE) Jumps 7.53% on Septemb... [Published Equities.com - Sep 20 2014]
Curcumin Suppresses Crosstalk between Colon Can... [Published Plosone.org - Sep 20 2014]
Washington People: Ramaswamy Govindan​​​​​​​​ [Published WUSTL Medicine & Healthcare News - Sep 20 2014]
Leading Health Care Stock for Small-Cap Stars i... [Published Equities.com - Sep 19 2014]
Halozyme's PEGPH20 Study S1313 Clinical Hold Li... [Published Nasdaq - Sep 19 2014]
Lpath raises $12.5 million [Published U-T San Diego - Sep 19 2014]
Bristol-Myers' (BMY) Yervoy Label Expanded in C... [Published Zacks.com - Sep 19 2014]
Halozyme's PEGPH20 Study S1313 Clinical Hold Li... [Published Zacks.com - Sep 19 2014]
AKT1 and SELP Polymorphisms Predict the Risk of... [Published Plosone.org - Sep 19 2014]
Chronic [Published Oncology Times - Sep 19 2014]
Dystrophic Vs. Metastatic Calcification [Published Buzzle.com - Sep 19 2014]
Dystrophic Calcification: Causes and Symptoms [Published Buzzle.com - Sep 19 2014]
Tumor cells prep lymphatic cells to encourage b... [Published Chemotherapy Advisor - Sep 19 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Washington People: Ramaswamy Govindan​​​​​​​​ [Published WUSTL Medicine & Healthcare News - Sep 20 2014]
​ Robert Boston Ramaswamy Govindan, MD, is using next-generation sequencing to uncover genetic mutations that play a role in forming tumors. The discoveries could expand treatments for patients because drugs targeting some of these genetic changes already ...
Save Your Skin Foundation Applauds Health Canad... [Published Marketwire - Breaking News Releases - Sep 18 2014]
The immunotherapy treatment with long-term survival rates in some previously treated patients is now approved for use in newly diagnosed patients ...
Fare Thee Well, Tony Auth [Published Balloon Juice - Sep 16 2014]
That was the very last Tony Auth cartoon on my daily GoComics page, back on July 1st. I knew Auth was old enough to retire, but I didn’t realize why he was no longer drawing. From his “own” paper, the Philadelphia Inquirer: Tony Auth, 72, of ...
FDA approves Astellas and Medivation's expanded... [Published PBR - News - Sep 11 2014]
The US Food and Drug Administration (FDA) has granted approval to Astellas Pharma and Medivation's expanded use of Xtandi (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (CRPC). ...
Medivation and Astellas win expanded use for pr... [Published Tech Chronicles - Sep 11 2014]
San Francisco pharmaceutical company Medivation, and its partner Astellas Pharma, were celebrating Wednesday after winning federal permission to significantly expand the audience for their prostate cancer drug. The drug, Xtandi or enzalutamide, was first ...
1 2 3 4 5 6 7 8 9 10 ...

Audio/Video

sort by: Date | Relevance
The Fault In Our Stars [Published Slate Magazine - Jun 07 2014]
1

Press Releases

sort by: Date | Relevance
Allegheny Health Network Study Shows Improved S... [Published GlobeNewswire: Acquisitions News - Sep 18 2014]
Enrollment in Argos Therapeutics' Pivotal Phase... [Published GlobeNewswire: Advertising News - Sep 18 2014]
OXiGENE Initiates Phase 2 Study of Fosbretabuli... [Published GlobeNewswire: Acquisitions News - Sep 17 2014]
OncoGenex Announces Completion of Patient Enrol... [Published Financial Services - Sep 16 2014]
Immunicum presents updated survival data for IN... [Published GlobeNewswire: Acquisitions News - Sep 12 2014]
1 2 3 4 5
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.